Myelodysplastic Syndrome News

News

FDA Grants Approval to Imetelstat for Patients With Low to Intermediate-1 Risk Myelodysplastic Syndrome With Transfusion-Dependent Anemia

06/21/2024

The FDA granted approval to imetelstat for patients with low to intermediate-1 risk MDS with transfusion-dependent anemia requiring 4 or more red blood cell transfusion units over 8 weeks, who cannot derive benefit from...

The FDA granted approval to...

06/21/2024

Oncology

News

Azacitidine Maintenance Demonstrates Lower Disease Progression Rate Among Patients With High-Risk FLT3-Negative AML/MDS

03/05/2024

Amber Denham

According to a retrospective analysis, azacitidine maintenance is associated with a lower progression rate in patients with high-risk FLT3-negative acute myeloid leukemia or myelodysplastic syndrome.

According to a retrospective...

03/05/2024

Oncology

News

Oral Decitabine Cedazuridine Safe, Effective Alternative to Intravenous Decitabine for Patients With MDS or CML

02/21/2024

Amber Denham

Oral decitabine cedazuridine demonstrates safety and efficacy as an alternative to intravenous decitabine treatment among patients with myelodysplastic syndromes or chronic myelomonocytic leukemia, according to phase 3 study results.

Oral decitabine cedazuridine...

02/21/2024

Oncology

News

Assessment of Individualized MRD With NGS, ddPCR Effective for Early Detection of MDS Relapse

02/09/2024

Amber Denham

Evaluating individualized measurable residual disease with next-generation sequencing and droplet digital polymerase chain reaction is feasible and can be used for early detection of relapse among patients with myelodysplastic syndrome,...

Evaluating individualized...

02/09/2024

Oncology

News

Efficacy of Azacitidine Among Treatment-Naive Patients With Higher-Risk Myelodysplastic Syndromes

01/31/2024

Amber Denham

Azacitidine demonstrated low complete remission rates and low median overall survival as a frontline therapy for patients with high-risk myelodysplastic syndromes, according to a retrospective study.

Azacitidine demonstrated low...

01/31/2024

Oncology

News

Sabatolimab Plus Hypomethylating Agents as Frontline Therapy for Patients With Higher-Risk MDS

01/11/2024

Amber Denham

A phase 2 trial determined that the addition of sabatolimab to hypomethylating agents showed manageable safety, but did not result in a significant improvement in complete response rates or progression-free survival for untreated patients...

A phase 2 trial determined that...

01/11/2024

Oncology

Conference Coverage

Fedratinib Demonstrates Promising Efficacy in MDS/MPN and Chronic Neutrophilic Leukemia

12/09/2023

Janelle Bradley

Data from a phase 2 trial show fedratinib demonstrates promising clinical activity in patients with MDS/MPN and chronic neutrophilic leukemia.

Data from a phase 2 trial show...

12/09/2023

Oncology

Conference Coverage

Phase 3 IMerge Study Confirms Clinical Efficacy of Imetelstat in Lower-Risk MDS Across Risk Categories

12/09/2023

Janelle Bradley

Imetelstat improves red blood cell transfusion independence rates vs placebo in patients with lower-risk MDS relapsed/refractory to erythropoiesis-stimulating agents across different subgroups, according to data from the IMerge phase 3 study.

Imetelstat improves red blood...

12/09/2023

Oncology

News

Molecular Scoring System IPSS-M Demonstrates Superior Predictive Potential for Survival and AML Transformation Among Patients With MDS

10/30/2023

Jordan Kadish

Molecular scoring system IPSS-M demonstrated superior accuracy in predicting survival outcomes and acute myeloid leukemia transformation compared to IPSS-R among patients with myelodysplastic syndrome.

Molecular scoring system IPSS-M...

10/30/2023

Oncology

News

FDA Grants Approval to Ivosidenib for Patients With R/R Myelodysplastic Syndromes With IDH1 Mutation

10/26/2023

Jordan Kadish

On October 24, 2023, the FDA granted approval for ivosidenib, a small molecule inhibitor of IDH1, in the treatment of patients with R/R myelodysplastic syndromes with IDH1 mutation.

On October 24, 2023, the FDA...

10/26/2023

Oncology

Recent News

News

Osimertinib Lacks Activity in Neoadjuvant Setting for Early-Stage Non-Small Cell Lung Cancer With EGFR Mutation

08/08/2024

Stephanie Holland ;

Results from a phase 2 study demonstrated that neoadjuvant osimertinib did not improve the major pathological response rate among patients with early-stage non-small cell lung cancer harboring an EGFR mutation.

Results from a phase 2 study...

08/08/2024

Oncology

FDA Approval

FDA Approves Denileukin Diftitox for Patients With R/R Cutaneous T-Cell Lymphoma

08/08/2024

Amber Denham ;

The US Food and Drug Administration approved novel immunotherapy denileukin diftitox-cxdl for the treatment of patients with relapsed/refractory cutaneous T-cell lymphoma after at least 1 prior systemic therapy.

The US Food and Drug...

08/08/2024

Oncology

News

Tailored Dose-Dense Chemotherapy Improved Survival Outcomes Among Patients With High-Risk Early Breast Cancer

08/07/2024

Stephanie Holland ;

According to results from the phase 3 PANTHER trial, tailored and dose-dense chemotherapy in the adjuvant setting improved survival outcomes compared to standard chemotherapy among patients with high-risk early breast cancer.

According to results from the...

08/07/2024

Oncology

News

Frontline Treatment Management for Patients With FL Reduces Risk of High-Grade Transformation to DLBCL

08/07/2024

Amber Denham ;

A recent study demonstrated that frontline treatment management reduced the risk of high-grade transformation to diffuse large B-cell lymphoma among patients with follicular lymphoma, but not among patients with marginal zone lymphoma.

A recent study demonstrated that...

08/07/2024

Oncology

News

Optimal Sotorasib Dose for Patients With KRAS G12C-Mutated Advanced Non-Small Cell Lung Cancer

08/07/2024

Stephanie Holland ;

Results from a phase 2 study found that 960 mg of sotorasib is preferable to 240 mg among patients with previously treated KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer.

Results from a phase 2 study...

08/07/2024

Oncology

FDA Approval

FDA Approves Vorasidenib for Patients With IDH1/IDH2-Mutated Grade 2 Astrocytoma or Oligodendroglioma

08/06/2024

Stephanie Holland ;

Based on results from the INDIGO trial, the FDA has approved vorasidenib for adult and pediatric patients 12 years and older with grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation following surgery.

Based on results from the INDIGO...

08/06/2024

Oncology

FDA Approval

FDA Approves Afamitresgene Autoleucel for Certain Unresectable or Metastatic Synovial Sarcoma

08/02/2024

Allison Casey ;

On August 2, 2024, the US Food and Drug Administration (FDA) granted accelerated approval to afamitresgene autoleucel for the treatment of adult patients with certain unresectable or metastatic synovial sarcomas who had received prior...

On August 2, 2024, the US Food...

08/02/2024

Oncology

FDA Approval

FDA Approves Dostarlimab Plus Chemotherapy for Patients With Primary Advanced or Recurrent Endometrial Cancer

08/01/2024

Allison Casey ;

The FDA approved dostarlimab plus carboplatin and paclitaxel, followed by single-agent dostarlimab for patients with primary advanced or recurrent endometrial cancer.

The FDA approved dostarlimab...

08/01/2024

Oncology

News

Iadademstat and Azacitidine Combination Therapy Demonstrates Manageable Safety, Promising Efficacy for Patients With Newly Diagnosed AML

08/01/2024

Amber Denham ;

The first-line combination of iadademstat and azacitidine demonstrates a manageable safety profile and promising results among patients with acute myeloid leukemia, according to phase 2 results from the ALICE trial.

The first-line combination of...

08/01/2024

Oncology

News

Effect of Food on Selumetinib Dosing for Adolescent Patients With Neurofibromatosis Type 1 With Plexiform Neurofibromas

08/01/2024

Allison Casey ;

In the phase 1 trial, the addition of a low-fat meal with doses of selumetinib did not significantly impact selumetinib exposure or gastrointestinal toxicities among adolescent patients with neurofibromatosis type 1 with plexiform...

In the phase 1 trial, the...

08/01/2024

Oncology